Murali Shyamsundar

Aug 21, 2024 | digitalcommons.library.tmc.edu | Thomas Hills |Elizabeth Lorenzi |Lindsay Berry |Murali Shyamsundar

BACKGROUND: The efficacy of simvastatin in critically ill patients with coronavirus disease 2019 (Covid-19) is unclear. METHODS: In an ongoing international, multifactorial, adaptive platform, randomized, controlled trial, we evaluated simvastatin (80 mg daily) as compared with no statin (control) in critically ill patients with Covid-19 who were not receiving statins at baseline.

Mar 11, 2024 | mdpi.com | John Corcoran |Mark Hew |Murali Shyamsundar |Ben Attwood

All articles published by MDPI are made immediately available worldwide under an open access license. No specialpermission is required to reuse all or part of the article published by MDPI, including figures and tables. Forarticles published under an open access Creative Common CC BY license, any part of the article may be reused withoutpermission provided that the original article is clearly cited. For more information, please refer tohttps://www.mdpi.com/openaccess.